Becton Dickinson Beheer

Beheer criteriumcontroles 3/4

De CEO Becton Dickinson is Tom Polen, benoemd in Apr2017, heeft een ambtstermijn van 7.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 17.31M, bestaande uit 7.6% salaris en 92.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.02% van de aandelen van het bedrijf, ter waarde R$ 76.60M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.9 jaar en 7 jaar.

Belangrijke informatie

Tom Polen

Algemeen directeur

US$17.3m

Totale compensatie

Percentage CEO-salaris	7.6%
Dienstverband CEO	7.6yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.9yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Tom Polen's beloning veranderd ten opzichte van Becton Dickinson's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	US$17m	US$1m	US$1b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$1b
Sep 30 2022	US$17m	US$1m	US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	n/a	n/a	US$1b
Sep 30 2021	US$14m	US$1m	US$2b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	n/a	n/a	US$2b
Sep 30 2020	US$12m	US$952k	US$245m
Jun 30 2020	n/a	n/a	US$786m
Mar 31 2020	n/a	n/a	US$923m
Dec 31 2019	n/a	n/a	US$760m
Sep 30 2019	US$6m	US$900k	US$1b
Jun 30 2019	n/a	n/a	US$784m
Mar 31 2019	n/a	n/a	US$926m
Dec 31 2018	n/a	n/a	US$894m
Sep 30 2018	US$6m	US$850k	US$159m

Compensatie versus markt: De totale vergoeding ($USD 17.31M ) Tom } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 5.75M ).

Compensatie versus inkomsten: De vergoeding van Tom is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Tom Polen (51 yo)

7.6yrs

Tenure

US$17,309,938

Compensatie

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been Director at Walgreens Boots Alliance,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Polen	President	7.6yrs	US$17.31m	0.020% R$ 76.6m
Christopher DelOrefice	Executive VP & CFO	3.2yrs	US$5.21m	0.0044% R$ 16.7m
Shana Neal	Executive VP & Chief People Officer	2.6yrs	US$5.89m	0.0057% R$ 21.3m
Michael Garrison	Executive VP & President of Medical segment	2.2yrs	US$3.65m	0.0019% R$ 7.0m
Thomas Spoerel	Senior VP	5.1yrs	geen gegevens	0.00071% R$ 2.7m
Elizabeth McCombs	Executive VP & Chief Technology Officer	3.6yrs	geen gegevens	geen gegevens
Joseph Smith	Senior VP	3yrs	geen gegevens	geen gegevens
Denise Fleming	Executive VP of Technology & Global Services and Chief Information Officer	2.8yrs	geen gegevens	geen gegevens
Greg Rodetis	Head of Investor Relations	1.1yrs	geen gegevens	geen gegevens
Michelle Quinn	Executive VP & General Counsel	1.8yrs	geen gegevens	0.0017% R$ 6.4m
Claudia Curtis	Senior VP	no data	geen gegevens	geen gegevens
Carla Burigatto	Senior VP & Chief Communications Officer	no data	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van B1DX34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Polen	President	4.8yrs	US$17.31m	0.020% R$ 76.6m
Joseph Smith	Senior VP	3yrs	geen gegevens	geen gegevens
John DeFord	Co-Chair of Scientific Advisory Board	3.5yrs	geen gegevens	geen gegevens
Robert Eckert	Independent Director	8.2yrs	US$362.77k	0.0028% R$ 10.6m
Timothy Ring	Independent Director	7.8yrs	US$332.78k	0.020% R$ 76.8m
Jeffrey Henderson	Independent Director	6.3yrs	US$357.78k	0.0019% R$ 7.3m
Christopher Ian Jones	Independent Director	14.3yrs	US$362.78k	0.0074% R$ 27.9m
Bertram Scott	Lead Independent Director	22.2yrs	US$372.78k	0.012% R$ 45.8m
Catherine Burzik	Independent Director	11.8yrs	US$357.78k	0.0046% R$ 17.2m
William Brown	Independent Director	2.8yrs	US$332.78k	0.00087% R$ 3.3m
Claire Fraser-Liggett	Member of Scientific Advisory Board & Independent Director	18yrs	US$340.15k	0.0078% R$ 29.5m
Carrie Byington	Independent Director	3.1yrs	US$337.78k	0.00099% R$ 3.7m

7.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van B1DX34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

Becton Dickinson Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

Becton, Dickinson and Company Announces Executive Changes

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Recent updates

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Board Increases Quarterly Dividend, Payable on December 30, 2022

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

BD Launches Cloud Software Solution to Streamline Flow Cytometry Research

BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay

Becton, Dickinson and Company Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Becton, Dickinson and Company Certest Biotec Announce Commercial Launch of Monkeypox Test

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2022

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Parata Systems, LLC from Frazier Healthcare Partners.

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD Announces Voluntary Recall on Intraosseous Products

Becton, Dickinson and Company Appoints Simon Campion as Executive Vice President and President of the Medical Segment, Effective July 1, 2022

Becton, Dickinson and Company (NYSE:BDX) (BD) entered into a definitive agreement to acquire Parata Systems, LLC from Frazier Healthcare Partners for $1.5 billion.

Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2022

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2022

New Becton, Dickinson and Company Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry

Becton, Dickinson and Company to Report Q2, 2022 Results on May 05, 2022